MS Contin is the brand name for a controlled-release tablet form of morphine, a powerful opioid pain medication. Unlike immediate-release morphine, which is taken every four hours, MS Contin is designed to release the drug slowly over time and is typically taken every 12 hours. It is reserved for severe, continuous pain, most commonly in people undergoing active cancer treatment or receiving palliative care.
How MS Contin Works
Morphine, the active ingredient in MS Contin, relieves pain by binding to opioid receptors in the brain and throughout the nervous system. When morphine attaches to these receptors, it activates the body’s built-in pain-suppression pathways while also blocking pain signals from reaching the brain. The combined effect is a significant reduction in how much pain you feel.
What makes MS Contin different from regular morphine tablets is its controlled-release design. A standard morphine tablet reaches roughly half its peak concentration in the bloodstream within about 30 minutes. MS Contin takes around 1.5 hours to reach that same point, spreading the drug’s effects over a much longer window. This means steadier pain relief with fewer doses per day, though peak levels are somewhat higher and trough levels somewhat lower compared to taking immediate-release morphine every four hours.
Who MS Contin Is Prescribed For
MS Contin is not a first-line painkiller. It is specifically intended for people with severe, chronic pain who need around-the-clock opioid relief for an extended period and who have already been taking daily immediate-release opioids. The FDA notes that some extended-release opioids like MS Contin should only be considered for patients who have been on immediate-release opioids daily for at least one week.
There is a clear list of situations where MS Contin should not be used:
- Acute or post-surgical pain. Using long-acting opioids for short-term pain actually increases the risk of developing long-term opioid dependence.
- As-needed pain relief. MS Contin is not meant to be taken only when pain flares up. It is designed for continuous, scheduled dosing.
- Opioid-naive patients. People who are not already tolerant to opioids face a much higher risk of dangerous side effects, particularly slowed breathing.
- Pain that is not expected to last. If the underlying cause of pain is temporary, shorter-acting options are more appropriate.
The 2022 CDC Clinical Practice Guideline for prescribing opioids reinforces this approach, recommending that clinicians start opioid therapy with immediate-release formulations rather than extended-release products. Extended-release opioids like MS Contin should be reserved for severe, continuous pain after other options have proven inadequate.
How the Tablets Must Be Taken
MS Contin tablets must be swallowed whole. They should never be split, chewed, crushed, or dissolved. The controlled-release design depends on the tablet’s structure to meter out morphine gradually. Breaking that structure in any way can release the entire dose at once, which can cause a fatal overdose even in someone who has been taking the medication as prescribed. This is one of the most important safety points for anyone handling this medication.
Serious Safety Warnings
MS Contin carries the FDA’s most serious safety label, known as a Boxed Warning, covering several life-threatening risks.
The most critical risk is respiratory depression, a dangerous slowing of breathing. This risk is highest when first starting the medication or after a dose increase, because the body has not yet adjusted to the new level of morphine. Proper, gradual dose adjustments are essential to minimize this danger.
Addiction, misuse, and abuse are possible even when MS Contin is taken exactly as prescribed. Accidental ingestion by someone who does not have a prescription, particularly a child, can be fatal. The medication should be stored securely and out of reach at all times.
Taking MS Contin during pregnancy can cause neonatal opioid withdrawal syndrome, a condition where the newborn experiences withdrawal symptoms after birth that require medical intervention.
Dangerous Combinations
Mixing MS Contin with alcohol, sedatives, or anti-anxiety medications (benzodiazepines) is particularly dangerous. These substances all suppress the same brain circuits that control breathing, and their combined effects can be synergistic rather than simply additive. That means the risk of fatal respiratory depression is far greater than you might expect from either substance alone.
Alcohol plays a role in roughly 1 in 5 overdose deaths involving prescription opioids each year. Sleep medications, muscle relaxants, and other drugs that cause drowsiness carry similar risks when combined with MS Contin. If you are prescribed this medication, every other substance you take, including over-the-counter products, needs to be discussed with your prescriber.
Common Side Effects
Beyond the serious risks, morphine commonly causes constipation, nausea, drowsiness, dizziness, and itching. Constipation is nearly universal with long-term opioid use and does not improve with time the way other side effects often do. Most people on MS Contin need a bowel regimen alongside their pain medication. Nausea and drowsiness tend to be worst in the first few days and often lessen as the body adjusts.
How MS Contin Compares to Immediate-Release Morphine
The key difference is convenience and consistency. Immediate-release morphine works faster but wears off in about four hours, meaning you need multiple doses throughout the day and night. MS Contin provides a more even level of pain control with just two doses per day. However, it is not interchangeable with immediate-release morphine on a dose-for-dose basis. Switching between formulations requires careful calculation by a prescriber to avoid under- or overdosing.
Some people on MS Contin are also prescribed a small supply of immediate-release morphine for “breakthrough” pain, which is pain that spikes above the baseline level despite around-the-clock treatment. The two formulations serve different roles in an overall pain management plan.